A 58-year-old man with Child-Pugh class B cirrhosis secondary to hepatitis C presents for surveillance imaging. Triphasic CT of the abdomen shows a 12 mm nodule in the right lobe of the cirrhotic liver. The structure marked **A** demonstrates arterial phase hyperenhancement (wash-in). Portal venous phase imaging shows no wash-out, and there is no capsular enhancement. No threshold growth is documented on comparison with imaging from 8 months prior.
According to AASLD/LI-RADS criteria, what is the most appropriate next step in management?
A. Initiate sorafenib as first-line systemic therapy for presumed advanced HCC
B. Repeat imaging in 3–4 months to assess for additional LI-RADS criteria before diagnosing HCC
C. Perform ultrasound-guided biopsy to confirm the diagnosis before treatment
D. Proceed directly to liver transplantation as the nodule meets diagnostic criteria for HCC
Explanation
Why "Repeat imaging in 3–4 months to assess for additional LI-RADS criteria before diagnosing HCC" is right
LI-RADS 5 (definite HCC) requires arterial phase hyperenhancement (wash-in) PLUS at least TWO additional features: non-peripheral wash-out, enhancing capsule, or threshold growth. In this case, the nodule has only arterial wash-in without wash-out, capsular enhancement, or threshold growth. This nodule is LI-RADS 4 (probably HCC), not LI-RADS 5. Per AASLD guidelines, LI-RADS 4 lesions in cirrhotic patients require follow-up imaging at 3–4 months to look for evolution toward LI-RADS 5 criteria (particularly threshold growth or development of wash-out) before definitive diagnosis and treatment. Biopsy is not required and may be deferred in the cirrhotic setting given the high risk of bleeding and the ability to diagnose HCC radiologically.
Why each distractor is wrong
Proceed directly to liver transplantation: The nodule does not yet meet LI-RADS 5 criteria (lacks two of the three additional features). Transplantation is reserved for early-stage HCC meeting Milan criteria (single lesion ≤5 cm or ≤3 lesions ≤3 cm each) with confirmed diagnosis. Premature transplantation for a LI-RADS 4 lesion would be inappropriate resource allocation.
Perform ultrasound-guided biopsy: HCC is unique among solid tumors in that it can be diagnosed radiologically WITHOUT biopsy in the cirrhotic liver using LI-RADS criteria. Biopsy carries risk of hemorrhage in cirrhotic patients and is not indicated for LI-RADS 4 lesions; surveillance imaging is the standard approach.
Initiate sorafenib as first-line systemic therapy: Sorafenib is no longer first-line for advanced HCC (BCLC stage C with vascular invasion or extrahepatic spread). This nodule is not yet confirmed HCC, and even if it were, a 12 mm lesion without vascular invasion would be early-stage (BCLC 0 or A), managed with resection, ablation, or transplant—not systemic therapy. Additionally, atezolizumab + bevacizumab (IMbrave150) is now preferred over sorafenib for advanced HCC.
High-YieldNEET PG
LI-RADS 5 requires arterial wash-in PLUS ≥2 of: wash-out, capsule, or threshold growth. LI-RADS 4 lesions need surveillance imaging at 3–4 months; biopsy is not required in cirrhosis.
